July 2024

NEW YORK, July 29, 2024 /PRNewswire/ — Previous research has found that over 80 percent of people with opioid use disorder (OUD) do not receive evidence-based lifesaving medications. While access to these medications is better in New York City than elsewhere in the United States, numerous str

— Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) — — Obicetrapib lowered LDL-C by 36.3% at week 12 and

ALL INDICATORS SHOW GROWTH; EBITDA INCREASES BY DOUBLE DIGITS WITH STRONG MARGIN EXPANSION; NET PROFIT DOUBLES Consolidated revenues of €289.1 million, up 3.8% at constant exchange rates compared to the first half of 2023, driven by all major markets and distribution channels EBITDA of €46.2 mil

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: